202
Participants
Start Date
September 30, 2009
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
imatinib mesylate
Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
Placebo
Placebo to imatinib 100 mg film coated tablets
Novartis Investigative Site, New York
Novartis Investigative Site, New York
Novartis Investigative Site, Pittsburgh
Novartis Investigative Site, Pittsburgh
Novartis Investigative Site, Philadelphia
Novartis Investigative Site, Baltimore
Novartis Investigative Site, Durham
Novartis Investigative Site, Atlanta
Novartis Investigative Site, Miami Beach
Novartis Investigative Site, Weston
Novartis Investigative Site, Clearwater
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Knoxville
Novartis Investigative Site, Cleveland
Novartis Investigative Site, Cleveland
Novartis Investigative Site, Cincinnati
Novartis Investigative Site, Milwaukee
Novartis Investigative Site, Rochester
Novartis Investigative Site, Chicago
Novartis Investigative Site, St Louis
Novartis Investigative Site, Omaha
Novartis Investigative Site, Oklahoma City
Novartis Investigative Site, Dallas
Novartis Investigative Site, Houston
Novartis Investigative Site, Aurora
Novartis Investigative Site, Phoenix
Novartis Investigative Site, Los Angeles
Novartis Investigative Site, San Francisco
Novartis Investigative Site, Portland
Novartis Investigative Site, Boston
Novartis Investigative Site, Boston
Novartis Investigative Site, Boston
Novartis Investigative Site, Minneola
Novartis investigative site, Innsbruck
Novartis Investigative Site, Vienna
Novartis Investigative Site, Brussels
Novartis Investigative Site, Leuven
Novartis Investigative Site, Calgary
Novartis Investigative Site, Edmonton
Novartis Investigative Site, London
Novartis Investigative Site, Montreal
Novartis Investigative Site, Ottawa
Novartis investigative site, Toronto
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Clamart
Novartis Investigative Site, Berlin
Novartis Investigative Site, Cologne
Novartis Investigative Site, Dresden
Novartis Investigative Site, Giessen
Novartis Investigative Site, Greifswald
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Hanover
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Homburg
Novartis investigative site, Löwenstein
Novartis Investigative Site, München
Novartis Investigative Site, Regensberg
Novartis Investigative Site, Würzberg
Novartis Investigative Site, Bologna
Novartis Investigative Site, Pavia
Novartis Investigative Site, Pisa
Novartis Investigative Site, Roma
Novartis Investigative Site, Bunkyō City
Novartis Investigative Site, Hamamatsu
Novartis Investigative Site, Mitaka
Novartis Investigative Site, Okayama
Novartis Investigative Site, Sendai
Novartis Investigative Site, Suita
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Seoul
Novartis Investigative Site, A Coruña
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Caceras
Novartis Investigative Site, Las Palmas de Gran Canarias
Novartis Investigative Site, Madrid
Novartis Investigative Site, Málaga
Novartis investigative site, San Cristóbal de La Laguna
Novartis Investigative Site, Santa Cruz de Tenerife
Novartis Investigative Site, Santander
Novartis Investigative Site, Seville
Novartis investigative site, Valencia
Novartis Investigative Site, Valladolid
Novartis Investigative Site, Lund
Novartis Investigative Site, Stockholm
Novartis Investigative Site, Umeå
Novartis Investigative Site, Uppsala
University Hospital Basel, Basel
Novartis Investigative Site, Bern
Novartis Investigative Site, Lausanne
Novartis Investigative Site, Sankt Gallen
Novartis Investigative Site, Cambridge
Novartis Investigative Site, Clydebank
Novartis Investigative Site, London
Novartis Investigative Site, Newcastle upon Tyne
Novartis Investigative Site, Sheffield
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY